


Daring to Go Beyond

Celltrion IR Presentation

UBS Asian Investment Conference 2026



Disclaimer

This document contains "forward-looking statements" - that is statements related to future not past events. In this context "forward-looking statements" often address our expected future business and financial performance and often contain words such as "expects" "anticipates" "intends" "plans" "believes" "seeks" or "will". "Forward-looking statements" by their nature address matters that are to different degrees uncertain. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The financial information contained in this document is consolidated earnings results based on K IFRS. This document is provided for the convenience of investors only before the external review is completed. The review outcomes may cause some changes in this document.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.



CONTENTS

01. Business Overview

02. Commercial Update

03. R&D and Manufacturing Update

01

Business Overview

Celltrion Growth Trend



2015-2025 CAGR

22%

Celltrion
(2015-2026)



10%


Global Biologics



6%

Global Pharma

Celltrion Revenue Growth Trend



*Source: Celltrion, IQVIA, Bloomberg

*Celltrion's 2025 and 2026 revenue figures are based on Bloomberg consensus estimates.

Biosimilar

- 11 products commercialized
- Expected to expand to 41 products by 2038
- Providing stable cash flow for future growth

CDMO


- Expansion of CDMO to meet strong market demand
- Order backlog: KRW 100bn (1Q25) → KRW 1tn (1Q26)
- Plan to leverage manufacturing bases in Korea and U.S

Novel Drug

- 18 pipeline candidates
- Strong focus on ADC and MsAb¹
- Ongoing development of hyaluronidase and peptides
- Dual-track strategy for L/O and commercialization

1. MsAb: Multi-specific Antibody.

Vertically Integrated Competencies




2026 Sales Guidance



High-Margin Products Expansion and Stable Cost Structure **Boost Profitability and Earnings Growth**
Biosimilar & Novel Drug Pipeline Expansion **Reinforces Growth Foundation**


[Unit: KRW trillion]



1. UC: Ulcerative Colitis

2026 Operating Profit Guidance

- With a stable cost structure, continued quarterly growth in OP is expected, driven by the expansion of high-margin Young products



* Operating profit excluding temporary utilization loss due to shutdown from scheduled maintenance at the U.S. plant

Key Drivers of OP Improvement

- 1 Growth of high-margin Young products**
 - ✓ Strong growth expected in '26 H2 from newly-launched products (<1 year since launch)
 - Omlyclo & Eydenzelt to be launched in the U.S.
 - Zymfentra growth set to accelerate
- 2 Greater fixed cost leverage from top-line growth in H2**
 - ✓ Improved SG&A efficiency and profitability driven by economies of scale as revenue expands
- 3 Normalized operations at Branchburg site**
 - ✓ Scheduled maintenance completed
 - ✓ CMO production and validation of in-house products underway from Q2

1Q26 Financial Highlights

Revenue Grew 36% YoY and Profit More than Doubled

Driven by Rapid Uptake of Five New Launches and Growth of High-Margin Young Products

[Unit: KRW billion]

	1Q26	4Q25	QoQ	1Q25	YoY
Sales	1,145.0	1,330.2	-13.9%	841.9	+36.0%
Biologics	974.2	1,252.3	-22.2%	767.6	+26.9%
Non-Biologics	170.8	77.9	+119.3%	74.3	+129.9%
Operating Profit	321.9	475.2	-32.3%	149.4	+115.5%
OP Margin	28.1%	35.7%	-7.6%p	17.7%	+10.4%p

Sales Increased +36.0% YoY

- High-margin Young biologics products, including five products launched in 2025, grew rapidly (+67% YoY), driving overall revenue growth
- Non-biologics revenue +130% YoY, driven by TEVA CMO revenue

OP Increased +115.5% YoY


- The OP margin improved from 17.7% to 28.1% YoY, driven by the normalization of merger-related impact and a more favorable sales mix
- Excluding temporary utilization loss due to scheduled maintenance at the U.S. plant, the OP margin remained in the 30% range. Operations at the U.S. plant have fully normalized, with no related impact is expected from Q2 onward
- Further penetration of five new launches and geographic expansion to lift the high-margin product mix, supporting sustained profitability improvement. Additional margin upside expected from raw material localization and production process optimization

Global Biologics Sales




- Q1 2026 Young product sales reached KRW 581.2bn (+67% YoY), with mix expanding to a record 60% of total revenue
- High-margin Young products expected to accelerate further into H2, driving mix expansion up to 70% for FY2026

Quarterly Comparison



Annual Forecast



* Advanced: Remsima, Truxima, Herzuma / Young: RemsimaSC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt

* 2023: Pre-merger Celltrion Healthcare's sales

Global Biologics Sales (by Product)





- High-margin Young products sales +KRW 234.0bn YoY, led by ramp-up of five new launches recording combined revenue of KRW 211.3bn
Zymfentra achieved 4x revenue growth, supported by expanded insurance coverage and increased prescriptions
- Advanced products maintained solid market share and demand, with slight sales decline driven by customer inventory adjustments following strong prior-quarter shipments and selective tender participation with focus on high-margin channels. Stable annual sales expected, supported by liquid-formulation Remsima launch in Europe and increased long-term Truxima supply contracts in the U.S.

High-margin Young Products ▲ KRW 234.0 bn

Advanced Products* ▼ KRW 27.4 bn

[Unit: KRW billion]




* 5 new products: Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt
* Advanced Products: Launched before 2020 / Young Products: Launched between 2020–2024 / 5 new products: Launched in 2025 and thereafter

02


Commercial Update

Biosimilar Market Landscape



1. Number of companies that conducted global clinical trials(pre-clinical to phase III) on the same molecules of Celltrion's launched or portfolio products;
2. Based on FY2023 sales; 3. Companies developing two or more products with the same molecules as those in our pipeline (aside from the Key Competitors);
4. Competitors with annual biosimilar sales of over \$500 million; 5. Number of products: the sum of FDA and EMA-approved monoclonal antibody biosimilars and disclosed pipeline products

Revenue Generation Capability




- ☑ Only a few companies that secured stable supply, sales networks, and a robust pipeline have survived
- ☑ Emerging biotech companies are increasingly entering the market; however, they often face difficulty in generating sustainable revenue

Biosimilars Portfolio



Category	Product	Molecule	Original	Indications	US Status	EU Status
Advanced Products	Remsima/ Inflectra	Infliximab	Remicade®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	2H16 Launched	1H13 Launched
	Truxima	Rituximab	Rituxan®/ MabThera®	Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), etc.	2H19 Launched	1H17 Launched
	Herzuma	Trastuzumab	Herceptin®	HER2-Positive Metastatic Breast Cancer(MBC), Early Breast Cancer(EBC), etc.	1H20 Launched	1H18 Launched
Young Products	Remsima SC	Infliximab	Remicade®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	-	1H20 Launched
	Zymfentra	Infliximab	Novel Drug	Ulcerative Colitis(UC), Crohn's Disease(CD)	1H24 Launched	-
	Vegzelma	Bevacizumab	Avastin®	Metastatic Colorectal Cancer(MCC), Non-Small Cell Lung Cancer(NSNLC), etc.	1H23 Launched	2H22 Launched
	Yuflyma	Adalimumab	Humira®	Rheumatoid Arthritis(RA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	1H23 Launched	1H21 Launched
	SteQeyma	Ustekinumab	Stelara®	Psoriasis(Ps), Psoriatic Arthritis(PsA), Ulcerative Colitis(UC), Crohn's Disease(CD), etc.	1H25 Launched	2H24 Launched
	Omlyclo	Omalizumab	Xolair®	Allergic Asthma, Chronic Spontaneous Urticaria(CSU), etc.	2H26 Planned launch	2H25 Launched
	Eydenzelt	Aflibercept	Eylea®	Wet age-related Macular Degeneration(AMD), Diabetic Macular Edema(DME), etc.	2H26 Planned launch	2H25 Launched
	Stoboclo & Osenvelt	Denosumab	Prolia® & Xgeva®	Osteoporosis, Multiple Myeloma(MM), Giant Cell Tumor(GCT), etc.	2H25 Launched	2H25 Launched
	Avtozma	Tocilizumab	Actemra®	Rheumatoid Arthritis(RA), Giant Cell Arteritis(GCA), Systemic Juvenile Idiopathic Arthritis(SJIA), etc.	2H25 Launched	2H25 Launched

Biosimilar Achievements




29%

Global M/S of products aged 3+ years

KRW 533 billion


Avg. revenue per product aged 3+ years in 2025

- Sustained market leadership in Europe and the U.S. & Securely established a leading global position
- First to launch a liquid formulation of infliximab in March, demonstrating early success with national tender wins in Norway and Denmark
- The only company globally with SC, lyophilized, and liquid formulations, supporting further market share gains and leadership strengthening



* Based on infliximab IV market (Excluding SC)

* Source: IQVIA, Farminform




* Based on infliximab IV market (Excluding SC)

* Source: IQVIA, Symphony Health

Truxima (Rituximab) & Herzuma (Trastuzumab)




- Truxima maintains a stable market share of over 30% across both the U.S. and European markets
- Herzuma retains No. 1 position despite temporary declines in parts of Europe driven by tender cycles. Continues strong growth in Japan
- Future launch of Herzuma SC is expected to strengthen competitiveness through formulation diversification and drive further M/S expansion



* Market share based on prescription volume

* Source : IQVIA, Farminform, Symphony Health




* Market share based on prescription volume

* Source : IQVIA, Farminform


Yuflyma (Adalimumab) & Vegzelma (Bevacizumab)



- Yuflyma maintains No. 1 share in the European adalimumab market, accelerating U.S. penetration with higher-margin Low-WAC sales
- Vegzelma retains No. 1 in Europe, surpassing 30% share for the first time. Market share continues to rise in the U.S. as sales channels diversify



* Market share based on prescription volume * Source: IQVIA, Farminform, Symphony Health




* Market share based on prescription volume * Source: IQVIA, Farminform, Symphony Health

Global Sales Trend of Five New Products

- Led by Omlyclo, launched as a first mover without competing biosimilars, the newly launched product portfolio expanded broadly, recording combined sales of KRW 211.3bn (approximately 10x YoY growth)
- Despite the typical trend of weaker Q1 sales, the combined sales of the five newly launched products still delivered strong QoQ growth at +16%
- Growth momentum to accelerate in H2 with the U.S. launches of Omlyclo and Eydenzelt, as well as the addition of UC indication for Steqeyma

Global Sales of Five New Products




Global status of Five New Products

	▪ Launched in Europe (24.11) and the U.S. (25.03) → Secured approval of the AI formulation in Canada, completing the full dosages and formulations range → Strengthened product competitiveness through a differentiated AI formulation versus the originator → An additional UC indication in Europe expected
 	▪ Launched in Europe (25.12) and the U.S. (25.07) → Listed as a preferred drug by three of the top 5 PBMs in the U.S. → Secured over 60% reimbursement coverage in the U.S. market
	▪ Launched in Europe (25.09) → Market leadership driven by first-mover advantage and diversified formulations (AI, PFS) → Achieved over 60% M/S in Spain within three months of launch → U.S. market launch planned in H2
	▪ Launched in Europe (26.01) and the U.S. (25.10) → Tenders ramping up through the RA portfolio bundling strategy → U.S. PBM listings progressing smoothly
	▪ Launched in Europe (25.12) → Secured a major U.K. tender immediately upon launch, establishing a supply base → U.S. market launch planned in H2


Zymfentra & Remsima SC (Infliximab SC)



- Zymfentra has delivered steady quarterly prescription growth since launch, establishing its position as a novel therapy in the U.S. autoimmune disease market
- Remsima SC surpasses 30% market share in EU5, with continued growth in non-EU5 markets



* Source: IQVIA SMART WSP(Weekly Sales Perspectives)



1. Based on EU5 infliximab market

* Data based on SC dose-adjusted prescription volume * Source: IQVIA, Farminfo

03

R&D and Manufacturing Update


Biosimilar Pipeline

- Following successful 2025 pipeline launches, next-generation pipeline development is on track, with a >4x target market expansion by 2038
 - Streamlined phase 3 patient enrollment across key pipelines is expected to reduce development costs
- : CT-P51(KEYTRUDA® Biosimilar) 606 → 220 patients, CT-P55(COSENTYX® Biosimilar) 375 → 153 patients, with IND¹ amendment approvals underway (completed in EU and Korea)

R&D Progress

Indication	Product Name	Global Market Size (2024)	Development Status	
			US	EU
Autoimmune Diseases	CT-P53 (OCREVUS® Biosimilar)	\$8.2bn	In Phase 3 Clinical Trial	
	CT-P55 (COSENTYX® Biosimilar)	\$9.9bn	In Phase 3 Clinical Trial	
	CT-P52 (TALTZ® Biosimilar)	\$7.0bn	In Phase 1 Clinical Trial	
	CT-P45 (Undisclosed)	-	IND submission planned	
	CT-P68 (Undisclosed)	-	IND submission planned	
Oncology	CT-P6 SC (HERCEPTIN SC® Biosimilar)	\$1.3bn ²	-	Regulatory filing submitted
NSCLC ³	CT-P51 (KEYTRUDA® Biosimilar)	\$32.7bn	In Phase 3 Clinical Trial	
Multiple Myeloma	CT-P44 (DARZALEX® Biosimilar)	\$11.7bn	In Phase 3 Clinical Trial	

Portfolio Status



* Source: IQVIA, J&J(DARZALEX)

1. IND (Investigational New Drug Application): A regulatory submission to obtain approval from relevant authorities to commence clinical trials in humans

2. Based on the Trastuzumab market in Europe (2024)

3. NSCLC: Non-Small Cell Lung Cancer

Innovative Drug Pipeline

ADC

CT-P70_cMET

NSCLC¹ / CRC² /
Gastric cancer

CT-P71_Nectin-4

UC³ / Breast cancer /
Prostate cancer

CT-P73_CD142

Cervical cancer /
H&N⁴ / CRC

CT-P74

Solid cancer

NBD10

Solid cancer

NBD21

Solid cancer

NBD08

Solid cancer

NBD11

Solid cancer

NBD13

Solid cancer

NBD15

Solid cancer

Multi-specific antibodies

CT-P72_HER2 x CD3

Breast cancer / CRC /
Gastric cancer /
Endometrial cancer

NBD18

Solid cancer

NBD04

Hematologic cancer

NBD05

Hematologic cancer

Recombinant Protein


CT-P77_FcRn

Myasthenia gravis

Peptide

CT-G32

Quad-Agonist
Obesity Drug



Novel Drug Development Status

- Consecutive FDA Fast Track designations for CT-P70 and CT-P71 demonstrate the global value of ADC therapeutics in high-risk cancer indications, with Fast Track applications for CT-P72 and CT-P73 planned within the year
- Enhancing additional corporate value by platformizing hyaluronidase-based subcutaneous (SC) technology and accelerating drug development through open innovation



CT-P70 _cMET NSCLC ¹ / CRC ² / Gastric cancer	Jan 2026: FDA Fast Track Designation ▪ Phase 1 Ongoing ▪ First read-out data disclosure planned for 2H 2026
CT-P71 _Nectin-4 UC ³ / Breast cancer / Prostate cancer	Apr 2026: FDA Fast Track Designation ▪ Phase 1 Ongoing ▪ First read-out data disclosure planned for 2H 2026
CT-P72 _HER2 x CD3 Breast cancer / Gastric cancer / CRC / Endometrial cancer	FDA Fast Track application planned within the year ▪ Phase 1 patient enrollment Ongoing
CT-P73 _CD142 Cervical cancer / H&N ⁴ / CRC	FDA Fast Track application planned within the year ▪ Phase 1 Ongoing ▪ First read-out data disclosure planned for 2H 2026

1. NSCLC, Non-Small Cell Lung Cancer; 2. CRC, Colorectal Cancer; 3. UC, Urothelial Carcinoma; 4. H&N, Head and Neck Cancer

Upon FDA Fast Track Designation

- Secured ongoing communication channel with the FDA
- Early consultation on clinical trial design and development strategy
- Priority Review
- Accelerated Approval



Through maximizing development efficiency,
**overall development timeline
can be shortened**

Current Capacity

316,000L of Own Drug Substance Capacity Sufficient to Meet Demand for Successor Pipelines



100,000L

- First to be approved by US FDA as animal cell culture facility in Asia



90,000L

- Capable of manufacturing drug substance and fill and finish of drug product



60,000L

- Small-scale, multi-product production supporting portfolio diversification



66,000L

- Immediate operational readiness through transferred assets and skilled workforce
- Planned expansion to 141,000L


Capacity Expansion Plan



① Cumulative CMO Order Backlog Surpasses KRW 1tn & CMO Business Expansion


2026.01 Order Value KRW 678.7bn	Client : Eli Lilly Contract Period : ~2029 (extendable) Production to begin immediately
2026.03 Order Value KRW 375.4bn	Client : Undisclosed (Global Pharma) Contract Period : 2027~2029 Confirmed Order Value: KRW 294.9bn (expandable up to KRW 375.4bn)

② In-house Pipeline Expansion



③ Expansion of U.S. Manufacturing Capacity to Address Tariffs

By securing DS manufacturing capacity up to 571kl through domestic and overseas expansion, **establishing a global supply chain to support pipeline expansion and meet CMO demand**



Global Manufacturing and Commercial Footprint



Advanced Therapeutics within Everyone's Reach

Thank you